STOCK TITAN

Catalyst Biosciences Inc - cbio STOCK NEWS

Welcome to our dedicated news page for Catalyst Biosciences (Ticker: cbio), a resource for investors and traders seeking the latest updates and insights on Catalyst Biosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Catalyst Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Catalyst Biosciences's position in the market.

Rhea-AI Summary
Totus Medicines (TOMD) announced the appointment of Nassim Usman, Ph.D., as President & CEO and the closing of a $66M Series B financing led by DCVC Bio. Neil Dhawan, Ph.D, will transition to CSO and Head of R&D. Dr. Usman brings extensive drug development experience and will lead the company through its next phase of growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.91%
Tags
management
-
Rhea-AI Summary
Catalyst Biosciences completes business combination with GNI Group Ltd., forming Gyre Therapeutics, Inc. The combined company will trade on Nasdaq under the symbol 'GYRE' starting October 31, 2023. Gyre aims to develop treatments for organ fibrosis and inflammatory diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1347.08%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.02%
Tags
dividends
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.51%
Tags
dividends
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.11%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.07%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.54%
Tags
none
Catalyst Biosciences Inc

Nasdaq:CBIO

CBIO Rankings

CBIO Stock Data

19.42M
1.83M
27.73%
8.75%
0.09%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
South San Francisco

About CBIO

catalyst is focused on developing novel medicines to address serious medical conditions for patients who need new or better treatment options. we used a scientific approach focused on protease-based therapeutic candidates to build a clinical-stage biopharmaceutical company whose current mission is to develop valuable therapies for patients with hemophilia. learn more about our hemophilia program. a protease is an enzyme that cleaves target proteins. learn more about proteases.